IA

Integra Lifesciences Holdings CorpNASDAQ IART Stock Report

Last reporting period 30 Sep, 2024

Updated 15 Nov, 2024

Last price

Market cap $B

1.387

Small

Exchange

XNAS - Nasdaq

IART Stock Analysis

IA

Uncovered

Integra Lifesciences Holdings Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

20/100

Low score

Market cap $B

1.387

Dividend yield

Shares outstanding

81.636 B

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. The company is headquartered in Princeton, New Jersey and currently employs 3,722 full-time employees. The firm operates through two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS segment consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield and Bactiseal. Its product offering includes CereLink in the Unites States and Europe. The Company’s TT segment focuses on three areas, which include complex wound surgery, surgical reconstruction and peripheral nerve repair. TT's regenerative platform includes multiple brands, such as Integra Dermal Matrices, AmnioExcel, SurgiMend, MicroMatrix and NeuraGen. The firm's manufacturing and research facilities are located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland.

View Section: Eyestock Rating